Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764
- November 20, 2018 Apellis Pharmaceuticals Expands Leadership Team, Appoints Adam Townsend as Chief Commercial Officer
- November 13, 2018 Apellis Pharmaceuticals Reports Third Quarter 2018 Business Update and Financial Results
- November 7, 2018 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
- November 1, 2018 Apellis Pharmaceuticals Announces Poster Presentations at the American Society of Hematology Annual Meeting
- September 28, 2018 Apellis Pharmaceuticals to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
- September 12, 2018 Apellis Pharmaceuticals Announces First Patient Dosed in Its Phase 3 Clinical Program for APL-2 in Patients With Geographic Atrophy
- September 4, 2018 Apellis Pharmaceuticals Announces that All Four Severely Anemic Soliris™-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria in Ongoing Phase 1b Trial Have Been Transitioned to APL-2 Monotherapy
- July 31, 2018 Apellis Pharmaceuticals Reports Second Quarter 2018 Business Update and Financial Results
- July 24, 2018 Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from FDA for the Treatment of Patients with Geographic Atrophy
- June 26, 2018 Apellis Pharmaceuticals Announces First Patient Enrolled in Phase 3 APL-2 Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Soliris™
Displaying 241 - 250 of 279